查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1636731

2030 年患者衍生異質骨移植模型市場預測：按模型類型、腫瘤類型、植入方法、應用、最終用戶和地區進行的全球分析

Patient-derived Xenograft Model Market Forecasts to 2030 - Global Analysis By Model Type, Tumor Type, Implantation Method, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，到 2024 年，患者來源的異質骨移植模型的全球市場價值將達到 4.943 億美元，預測期內複合年成長率為 14.3%，到 2030 年將達到 11.023 億美元。

在稱為患者源性異質骨移植（PDX）模型的實驗系統中，來自人類患者的腫瘤組織被移植到免疫力缺乏小鼠。該模型是癌症研究中的有用工具，因為原始腫瘤的遺傳特徵和表現型得以保留。與傳統的細胞株模型相比，PDX 模型可以更真實地描述人類癌症，並用於研究腫瘤生物學、測試療法和創建個人化醫療策略。

根據丹娜—法伯癌症研究所的一項研究，在 29 名晚期肉瘤患者中，有 16 名患者成功建立了 PDX 模型。

個人化醫療需求不斷成長

對個人化醫療的需求不斷成長正在推動患者來源的異質骨移植（PDX）模型市場。 PDX 模型使研究人員能夠研究患者特定的癌症生物學和藥物反應，這對於根據個別基因譜量身訂做治療方案至關重要。這種方法提高了治療效果並減少了副作用。癌症發生率的增加和基因組學的進步進一步增加了對個人化醫療的需求。

開發和維護成本高

建立和維護 PDX 模型需要大量的財務資源、專業知識和複雜的基礎設施。腫瘤植入和維持的複雜過程限制了其在小型研究機構中的使用。此外，免疫力缺乏動物和人類腫瘤樣本的高成本進一步增加了成本。這些經濟障礙對廣泛採用提出了挑戰。

癌症研究進展

癌症研究的進步正在為 PDX 模型市場創造機會。基於 CRISPR 的基因編輯、人工智慧主導的資料分析和人性化 PDX 模型等創新正在提高臨床前研究的準確性和效率。這些進步使研究人員能夠探索新的治療標靶，改善生物標記的發現，並加速藥物開發過程。此外，公共和私人對腫瘤學研究投資的增加正在推動對先進 PDX 模型的需求。

道德問題和監管挑戰

道德問題和監管挑戰威脅著 PDX 模型市場的成長。在研究中使用動物會引發倫理問題，並導致制定嚴格的指導方針，從而減緩或限制研究。 FDA 等監管機構正在採取措施減少對動物模型的依賴，這可能會影響市場動態。這些挑戰需要遵守複雜的通訊協定，並增加研究機構的營運成本和時限。

COVID-19 的影響：

由於實驗室營運、供應鏈和研究資金的中斷，COVID-19 的爆發對 PDX 模型市場產生了負面影響。由於資源被轉用於 COVID-19 研究，許多腫瘤學研究被推遲。然而，這場大流行強調了個人化醫療的重要性，並強調了 PDX 模型在癌症研究中的重要性。一旦限制放鬆，人們重新專注於創新的癌症治療方法，需求就會反彈。

預計滑鼠模型產業在預測期內將是最大的。

預計滑鼠模型部分在預測期內將佔據最大的市場佔有率。小鼠被廣泛使用，因為它們與人類基因相似，易於處理，並且與其他動物相比具有成本效益。小鼠提供了一個強大的平台來研究體內腫瘤生長、藥物療效和抗藥性機制。基於小鼠的 PDX 模型已建立協議，進一步支持其在臨床前腫瘤學研究中的優勢。

生物樣本庫產業預計在預測期內複合年成長率最高。

在預測期內，生物銀行產業預計將出現最高的複合年成長率，因為它負責保存源自患者的腫瘤樣本以供將來使用。生物庫允許研究人員取得不同的腫瘤檢體，以開發新的 PDX 模型和回顧性研究。此功能加快了藥物發現過程，同時確保了實驗的可重複性。對個人化醫療的日益重視增加了對生物樣本庫服務作為臨床前研究基礎設施重要組成部分的需求。

比最大的地區

預計北美地區在預測期內將佔據最大的市場佔有率。高癌症發病率、先進的醫療基礎設施以及對癌症研究的大量公共和私人投資等因素正在推動該地區的成長。主要產業參與者的出現進一步鞏固了北美在 PDX 模型採用方面的領導地位。此外，政府對精準醫療的支持也為此優勢做出了重大貢獻。

複合年成長率最高的地區：

預計亞太地區在預測期內將實現最高成長率。快速的都市化、不斷增加的醫療支出和不斷上升的癌症發病率正在推動該地區對 PDX 模型等先進研究工具的需求。向現代醫療保健的轉變使亞太地區成為主要的成長中心。此外，中國和印度等國家正大力投資生技和藥物研發，促進市場擴張。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭標基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球病患異質骨移植模型市場：依模型類型

  • 小鼠模型
    • 諾德SCID模型
    • 核子供應國集團模型
    • 其他免疫力缺乏模型
  • 大鼠模型
    • 免疫力缺乏大鼠模型
    • 人源化大鼠模型

第6章全球患​​者異質骨移植模型市場：按腫瘤類型

  • 胃腸道腫瘤
  • 婦科腫瘤
  • 呼吸道腫瘤
  • 乳癌腫瘤
  • 血液腫瘤
  • 泌尿系統腫瘤
  • 神經腫瘤
  • 其他腫瘤類型

第7章全球病患衍生異質骨移植模型市場：依移植方法分類

  • 皮下的
  • 原位
    • 手術植入
    • 非手術植入

第8章全球患者異質骨移植模型市場：依應用分類

  • 臨床前藥物開發
  • 生物標記分析
  • 生物銀行
  • 轉化研究

第9章全球病患衍生異質骨移植模型市場：依最終使用者分類

  • 製藥和生物技術公司
  • 學術/研究機構
  • 合約研究組織

第10章全球患者源性異質骨移植模型市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章 公司概況

  • Champions Oncology
  • Charles River Laboratories
  • Crown Bioscience
  • EPO Berlin-Buch
  • Hera BioLabs
  • Horizon Discovery Group
  • Inotiv
  • JSR Corporation
  • Oncodesign Precision Medicine
  • Pharmatest Services
  • Taconic Biosciences
  • The Jackson Laboratory
  • Urolead
  • WuXi AppTec
  • Xenopat
  • Xentech
Product Code: SMRC28372

According to Stratistics MRC, the Global Patient-derived Xenograft Model Market is accounted for $494.3 million in 2024 and is expected to reach $1102.3 million by 2030 growing at a CAGR of 14.3% during the forecast period. An experimental system known as a patient-derived xenograft (PDX) model involves implanting tumor tissues from human patients into immunocompromised mice. This model is a useful tool for cancer research because it maintains the original tumor's genetic and phenotypic features. Compared to conventional cell line models, PDX models provide a more realistic depiction of human cancer and are utilized to investigate tumor biology, test therapeutic medications, and create personalized medicine strategies.

According to Dana-Farber Cancer Institute study, 16 out of 29 patients with advanced sarcoma successfully established PDX models.

Market Dynamics:

Driver:

Rising demand for personalized medicine

The rising demand for personalized medicine is driving the patient-derived xenograft (PDX) model market. PDX models enable researchers to study patient-specific cancer biology and drug responses, making them essential for tailoring treatments to individual genetic profiles. This approach improves therapeutic efficacy and reduces adverse effects, aligning with the growing focus on precision oncology. The increasing prevalence of cancer and advancements in genomics further amplify the need for personalized medicine.

Restraint:

High costs of development and maintenance

Establishing and sustaining PDX models require significant financial resources, specialized expertise, and advanced infrastructure. The complex processes involved in tumor implantation and maintenance limit accessibility for smaller research organizations. Additionally, the high cost of immunodeficient animals and human tumor samples further increases expenses. These financial barriers pose challenges to widespread adoption.

Opportunity:

Advancements in cancer research

Advancements in cancer research are creating opportunities for the PDX model market. Innovations such as CRISPR-based gene editing, AI-driven data analysis and humanized PDX models are enhancing the accuracy and efficiency of preclinical studies. These advancements allow researchers to explore novel therapeutic targets, improve biomarker discovery, and accelerate drug development processes. Additionally, increasing public and private investments in oncology research are driving demand for advanced PDX models.

Threat:

Ethical concerns and regulatory challenges

Ethical concerns and regulatory challenges threaten the growth of the PDX model market. The use of animals in research raises ethical issues, leading to stringent guidelines that can delay or restrict studies. Regulatory agencies like the FDA have introduced measures to reduce reliance on animal models, potentially affecting market dynamics. These challenges necessitate compliance with complex protocols, increasing operational costs and timeframes for research organizations.

Covid-19 Impact:

The COVID-19 pandemic negatively impacted the PDX model market due to disruptions in laboratory operations, supply chains, and research funding. Many oncology studies were delayed as resources were diverted toward COVID-19 research. However, the pandemic underscored the importance of personalized medicine, highlighting the relevance of PDX models in cancer research. As restrictions eased, demand rebounded with renewed focus on innovative cancer therapies.

The mice models segment is expected to be the largest during the forecast period

The mice models segment is expected to account for the largest market share during the forecast period. Mice are widely used due to their genetic similarity to humans, ease of handling, and cost-effectiveness compared to other animals. They provide a robust platform for studying tumor growth, drug efficacy, and resistance mechanisms in vivo. The availability of well-established protocols for mice-based PDX models further supports their dominance in preclinical oncology research.

The biobanking segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biobanking segment is expected to witness the highest CAGR due to its role in preserving patient-derived tumor samples for future use. Biobanks enable researchers to access diverse tumor specimens for developing new PDX models and conducting retrospective studies. This capability accelerates drug discovery processes while ensuring reproducibility in experiments. The growing emphasis on personalized medicine drives demand for biobanking services as an essential component of preclinical research infrastructure.

Region with largest share:

The North America region is anticipated to account for the largest market share during the forecast period. Factors such as a high prevalence of cancer, advanced healthcare infrastructure, and significant public-private investments in oncology research drive regional growth. The presence of key industry players further strengthens North America's position as a leader in PDX model adoption. Additionally, government initiatives supporting precision medicine also contribute significantly to this dominance.

Region with highest CAGR:

The Asia Pacific region is anticipated to register the highest growth rate over the forecast period. Rapid urbanization, increasing healthcare expenditure, and rising cancer incidence drive demand for advanced research tools like PDX models in this region. The shift toward modern healthcare practices positions Asia Pacific as a key growth hub. Furthermore, countries like China and India are investing heavily in biotechnology and pharmaceutical R&D, fostering market expansion.

Key players in the market

Some of the key players in Patient-derived Xenograft Model Market include Champions Oncology, Charles River Laboratories, Crown Bioscience, EPO Berlin-Buch, Hera BioLabs, Horizon Discovery Group, Inotiv, JSR Corporation, Oncodesign Precision Medicine, Pharmatest Services, Taconic Biosciences, The Jackson Laboratory, Urolead, WuXi AppTec, Xenopat and Xentech.

Key Developments:

In December 2024, Can-Fite BioPharma Ltd. recently announced that its work titled The Liver Protective Effect of the Anti-Cancer Drug Candidate Namodenoson is mediated via Adiponectin will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium to take place at San Francisco & On Line, January 23-25.

In October 2019, Crown Bioscience announced the launch of a new tumor organoid drug development platform with the potential to significantly improve the predictivity and speed of preclinical drug discovery. The initial phase of the platform launch features the first commercially available 3D in vitro PDX-derived organoid (PDXO) models generated from CrownBio's uniquely-characterized library of 2500+ patient-derived xenograft (PDX) models.

In May 2015, Taconic Biosciences and Cellaria Biosciences have entered into a scientific collaboration designed to improve the utility of patient-derived xenografts (PDXs) in animal models for oncology and immuno-oncology research. Cellaria's novel methodologies for generating cells from patient tumors will complement Taconic's industry-leading portfolio of tissue humanized mouse models, which are said to be well suited as hosts for PDXs.

Model Types Covered:

  • Mice Models
  • Rat Models

Tumor Types Covered:

  • Gastrointestinal Tumors
  • Gynecological Tumors
  • Respiratory Tumors
  • Breast Cancer Tumors
  • Hematological Tumors
  • Urological Tumors
  • Neurological Tumors
  • Other Tumor Types

Implantation Methods Covered:

  • Subcutaneous
  • Orthotopic

Applications Covered:

  • Preclinical Drug Development
  • Biomarker Analysis
  • Biobanking
  • Translational Research

End Users Covered:

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutions
  • Contract Research Organizations

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Patient-derived Xenograft Model Market, By Model Type

  • 5.1 Introduction
  • 5.2 Mice Models
    • 5.2.1 NOD SCID Models
    • 5.2.2 NSG Models
    • 5.2.3 Other Immunodeficient Models
  • 5.3 Rat Models
    • 5.3.1 Immunodeficient Rat Models
    • 5.3.2 Humanized Rat Models

6 Global Patient-derived Xenograft Model Market, By Tumor Type

  • 6.1 Introduction
  • 6.2 Gastrointestinal Tumors
  • 6.3 Gynecological Tumors
  • 6.4 Respiratory Tumors
  • 6.5 Breast Cancer Tumors
  • 6.6 Hematological Tumors
  • 6.7 Urological Tumors
  • 6.8 Neurological Tumors
  • 6.9 Other Tumor Types

7 Global Patient-derived Xenograft Model Market, By Implantation Method

  • 7.1 Introduction
  • 7.2 Subcutaneous
  • 7.3 Orthotopic
    • 7.3.1 Surgical Implantation
    • 7.3.2 Non-surgical Implantation

8 Global Patient-derived Xenograft Model Market, By Application

  • 8.1 Introduction
  • 8.2 Preclinical Drug Development
  • 8.3 Biomarker Analysis
  • 8.4 Biobanking
  • 8.5 Translational Research

9 Global Patient-derived Xenograft Model Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical & Biotechnology Companies
  • 9.3 Academic & Research Institutions
  • 9.4 Contract Research Organizations

10 Global Patient-derived Xenograft Model Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Champions Oncology
  • 12.2 Charles River Laboratories
  • 12.3 Crown Bioscience
  • 12.4 EPO Berlin-Buch
  • 12.5 Hera BioLabs
  • 12.6 Horizon Discovery Group
  • 12.7 Inotiv
  • 12.8 JSR Corporation
  • 12.9 Oncodesign Precision Medicine
  • 12.10 Pharmatest Services
  • 12.11 Taconic Biosciences
  • 12.12 The Jackson Laboratory
  • 12.13 Urolead
  • 12.14 WuXi AppTec
  • 12.15 Xenopat
  • 12.16 Xentech

List of Tables

  • Table 1 Global Patient-derived Xenograft Model Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Patient-derived Xenograft Model Market Outlook, By Model Type (2022-2030) ($MN)
  • Table 3 Global Patient-derived Xenograft Model Market Outlook, By Mice Models (2022-2030) ($MN)
  • Table 4 Global Patient-derived Xenograft Model Market Outlook, By NOD SCID Models (2022-2030) ($MN)
  • Table 5 Global Patient-derived Xenograft Model Market Outlook, By NSG Models (2022-2030) ($MN)
  • Table 6 Global Patient-derived Xenograft Model Market Outlook, By Other Immunodeficient Models (2022-2030) ($MN)
  • Table 7 Global Patient-derived Xenograft Model Market Outlook, By Rat Models (2022-2030) ($MN)
  • Table 8 Global Patient-derived Xenograft Model Market Outlook, By Immunodeficient Rat Models (2022-2030) ($MN)
  • Table 9 Global Patient-derived Xenograft Model Market Outlook, By Humanized Rat Models (2022-2030) ($MN)
  • Table 10 Global Patient-derived Xenograft Model Market Outlook, By Tumor Type (2022-2030) ($MN)
  • Table 11 Global Patient-derived Xenograft Model Market Outlook, By Gastrointestinal Tumors (2022-2030) ($MN)
  • Table 12 Global Patient-derived Xenograft Model Market Outlook, By Gynecological Tumors (2022-2030) ($MN)
  • Table 13 Global Patient-derived Xenograft Model Market Outlook, By Respiratory Tumors (2022-2030) ($MN)
  • Table 14 Global Patient-derived Xenograft Model Market Outlook, By Breast Cancer Tumors (2022-2030) ($MN)
  • Table 15 Global Patient-derived Xenograft Model Market Outlook, By Hematological Tumors (2022-2030) ($MN)
  • Table 16 Global Patient-derived Xenograft Model Market Outlook, By Urological Tumors (2022-2030) ($MN)
  • Table 17 Global Patient-derived Xenograft Model Market Outlook, By Neurological Tumors (2022-2030) ($MN)
  • Table 18 Global Patient-derived Xenograft Model Market Outlook, By Other Tumor Types (2022-2030) ($MN)
  • Table 19 Global Patient-derived Xenograft Model Market Outlook, By Implantation Method (2022-2030) ($MN)
  • Table 20 Global Patient-derived Xenograft Model Market Outlook, By Subcutaneous (2022-2030) ($MN)
  • Table 21 Global Patient-derived Xenograft Model Market Outlook, By Orthotopic (2022-2030) ($MN)
  • Table 22 "Global Patient-derived Xenograft Model Market Outlook, By Surgical Implantation (2022-2030) ($MN)
  • Table 23 Global Patient-derived Xenograft Model Market Outlook, By Non-surgical Implantation (2022-2030) ($MN)
  • Table 24 Global Patient-derived Xenograft Model Market Outlook, By Application (2022-2030) ($MN)
  • Table 25 Global Patient-derived Xenograft Model Market Outlook, By Preclinical Drug Development (2022-2030) ($MN)
  • Table 26 Global Patient-derived Xenograft Model Market Outlook, By Biomarker Analysis (2022-2030) ($MN)
  • Table 27 Global Patient-derived Xenograft Model Market Outlook, By Biobanking (2022-2030) ($MN)
  • Table 28 Global Patient-derived Xenograft Model Market Outlook, By Translational Research (2022-2030) ($MN)
  • Table 29 Global Patient-derived Xenograft Model Market Outlook, By End User (2022-2030) ($MN)
  • Table 30 Global Patient-derived Xenograft Model Market Outlook, By Pharmaceutical & Biotechnology Companies (2022-2030) ($MN)
  • Table 31 Global Patient-derived Xenograft Model Market Outlook, By Academic & Research Institutions (2022-2030) ($MN)
  • Table 32 Global Patient-derived Xenograft Model Market Outlook, By Contract Research Organizations (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.